Guiding Light: Oncology Nurses’ Vital Role in Supporting Patients Through CLL Therapy

More than 200,000 people in the United States are living with a chronic lymphocytic leukemia (CLL) diagnosis, and it is responsible for approximately 4,410 U.S. deaths each year. The treatment landscape for CLL has changed dramatically in the past 10 years and there are now four FDA-approved Bruton tyrosine kinase inhibitors (BTKis), as well as venetoclax and chemoimmunotherapies, available to clinicians for their patients in the United States, while new, second- and third-generation BTKis and novel combination therapies are emerging. As a result, oncology nurses will be required to navigate varying dosing regimens and adverse event (AE) management approaches with their patients, in order to maximize therapy adherence.

In this Creative Educational Concepts (CEC) webcast, expert faculty will discuss strategies for differentiating patient- and disease-specific variables that inform CLL treatment selection, developing plans for managing new AEs, and addressing patient-related treatment barriers to improve adherence to CLL therapy.

At the conclusion of this activity, learners will be able to better:

• Differentiate patient- and disease-specific variables that inform CLL treatment selection
• Develop plans for managing AEs arising from new and emerging CLL treatment approaches, as well as long-term and late effects of treatments
• Incorporate strategies to address patient-related treatment barriers to improve adherence to CLL therapy

This activity is supported by educational grants from BeiGene USA, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.- both are Johnson & Johnson companies; and Lilly.

Oncology nurse practitioners (NPs) and RNs (academic and community)

Ms. Goodrich reports the following financial relationships:

Advisory Board: AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

Ms. Barkett reports no financial relationships to disclose.

Dr. Davids reports the following financial relationships:

Consultant: AbbVie Inc.; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Meyer Squibb Company; Lilly; Genentech, Inc.; GENMA Pharma; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Nuvalent; Secura Bio, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and TG Therapetics, Inc.

Grants: Ascentage Pharma; MEI Pharma, Inc.; and Novartis Pharmaceuticals Corporation

Other financial or material support: UpToDate – authorship royalties

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Evan Luberger (Planning Committee)
Katherine Lee, PharmD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sharon Tordoff (Planning Committee)